A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: The tacrolimus in combination, tacrolimus alone compared (TICTAC) trial

Circulation: Heart Failure

Volumn 4, Issue 2, 2011, Pages 129-137

  Baran, David A ^a   Zucker, Mark J ^a   Arroyo, Luis H ^a   Camacho, Margarita ^a   Goldschmidt, Marc E ^a   Nicholls, Stephen J ^b   Prevost Fernandez, Jeanne ^a   Carr, Candace ^a   Adams, Laura ^a   Pardi, Susan ^a   Hou, Vera ^a   Binetti, Maria ^a   McCahill, Jeanine ^a   Chichetti, Joanne ^a   Viloria, Valerie ^a   SanAgustin, Mary Gladys ^a   Ebuenga Smith, Jennifer ^a   Mele, Leslie ^a   Martin, Anthony ^a   Blicharz, Donna ^a   Wolski, Kathy ^b   Olesnicky, Ludmilla ^a   Qian, Fang ^a   Gass, Alan L ^c   Cohen, Marc ^a   more..

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Immunosuppression transplantation; Intravascular ultrasound; Orthotopic heart transplant; Randomized controlled trial; Transplantation

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC GRAFT REJECTION; CROSSOVER PROCEDURE; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BIOPSY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG COMBINATION; DRUG EFFECT; ENDOSCOPIC ECHOGRAPHY; GRAFT REJECTION; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TIME; UNITED STATES;

ADRENAL CORTEX HORMONES; ADULT; AGED; BIOPSY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; UNITED STATES;

EID: 79955937778     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.958520     Document Type: Article

References (31)

1. Lawrence SV. Heart transplants: Blessing or boondoggle? Forum Med. 1980;3:441-445.
2. Leaf A. Sounding board: The MGH trustees say no to heart transplants. N Engl J Med. 1980;302:1087-1088.
3. Griffith BP, Hardesty RL, Deeb GM, Starzl TE, Bahnson HT. Cardiac transplantation with cyclosporin a and prednisone. Ann Surg. 1982;196: 324-329. (Pubitemid 12052463)
4. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of fk 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc. 1991;23:3054-3057.
5. Mentzer RM Jr, Jahania MS, Lasley RD. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation: The US Multicenter FK506 study group. Transplantation. 1998;65:109-113. (Pubitemid 28100441)
6. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients: Mycophenolate mofetil investigators. Transplantation. 1998;66:507-515. (Pubitemid 28415379)
7. Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352:2705-2713. (Pubitemid 41007825)
8. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, Edwards N, Mancini DM. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000;342:613-619. (Pubitemid 30118413)
9. Baran DA, Segura L, Kushwaha S, Courtney M, Correa R, Fallon JT, Cheng J, Lansman SL, Gass AL. Tacrolimus monotherapy in adult cardiac transplant recipients: Intermediate-term results. J Heart Lung Transplant. 2001;20:59-70. (Pubitemid 32112386)
10. Lubitz SA, Baran DA, Alwarshetty MM, Pinney S, Kaplan S, Chan M, Courtney MC, Lansman SL, Spielvogel D, Gass AL. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant. 2006;25:699-706. (Pubitemid 43766576)
11. Baran DA, Zucker MJ, Arroyo LH, Alwarshetty MM, Ramirez MR, Prendergast TW, Goldstein DJ, Camacho M, Gass AL, Carr C, Cohen M. Randomized trial of tacrolimus monotherapy: Tacrolimus in combination, tacrolimus alone compared (the TICTAC trial). J Heart Lung Transplant. 2007;26:992-997. (Pubitemid 47494655)
12. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group: The international society for heart transplantation. J Heart Transplant. 1990;9:587-593.
13. Winters GL, Marboe CC, Billingham ME. The international society for heart and lung transplantation grading system for heart transplant biopsy specimens: Clarification and commentary. J Heart Lung Transplant. 1998;17:754-760. (Pubitemid 28396984)
14. Mehra MR, Ventura HO, Smart FW, Collins TJ, Ramee SR, Stapleton DD. An intravascular ultrasound study of the influence of angiotensinconverting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 1995;75: 853-854.
15. Yamani MH, Yousufuddin M, Starling RC, Tuzcu M, Ratliff NB, Cook DJ, Abdo A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Does acute cellular rejection correlate with cardiac allograft vasculopathy? J Heart Lung Transplant. 2004;23:272-276. (Pubitemid 38333083)
16. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710-1720. (Pubitemid 41641841)
17. Mehra MR, Ventura HO, Chambers R, Collins TJ, Ramee SR, Kates MA, Smart FW, Stapleton DD. Predictive model to assess risk for cardiac allograft vasculopathy: An intravascular ultrasound study. J Am Coll Cardiol. 1995;26:1537-1544.
18. Kobashigawa JA, Tobis JM, Starling RC, Tuzcu EM, Smith AL, Valantine HA, Yeung AC, Mehra MR, Anzai H, Oeser BT, Abeywickrama KH, Murphy J, Cretin N. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol. 2005;45:1532-1537. (Pubitemid 40615630)
19. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant. 2006;6:1248-1256. (Pubitemid 44030306)
20. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847-858. (Pubitemid 37025404)
21. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons W, First R. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6:1377-1386. (Pubitemid 44030320)
22. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Kucheryavaya AY, Rahmel AO, Hertz MI. Registry of the international society for heart and lung transplantation: Twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant. 2009;28:1007-1022.
23. Teuteberg JJ, Shullo MA, Zomak R, Toyoda Y, McNamara DM, Bermudez C, Kormos RL, McCurry KR. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: One-year outcomes. Am J Transplant. 2010;10:382-388.
24. Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L, Hobbs R, Smedira N, Starling RC. Thymoglobulin induction and steroid avoidance in cardiac transplantation: Results of a prospective, randomized, controlled study. Clin Transplant. 2008;22:76-81. (Pubitemid 351150006)
25. Crespo-Leiro M, Delgado J, Almenar L, Arizon JM, Blasco T, Brossa V, De la Fuente L, Diaz B, Fernandez-Yanez J, Garrido IP, Gomez Bueno M, Gonzalez Vilchez F, Lage E, Lopez Lopez L, Mirabet S, Perez-Villa F, Pulpon LA, Roig E, Vazquez de Prada JA. Steroid use in heart transplant patients in Spain in the current era: A multicenter survey. Transplant Proc. 2009;41:2244-2246.
26. Crespo-Leiro MG, Paniagua MJ, Franco R, Marzoa R, Grille Z, Naya C, Barge E, Rios R, Rodriguez JA, Calvino R, Cuenca JJ, Castro-Beiras A. Late steroid withdrawal after heart transplantation and incidence of acute rejection. Transplant Proc. 2007;39:2372-2374. (Pubitemid 47432703)
27. Nicholls SJ, Tuzcu EM, Schoenhagen P, Sipahi I, Crowe T, Kapadia S, Nissen SE. Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the reversal study). Am J Cardiol. 2005;96:1636-1639. (Pubitemid 41790383)
28. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: The Asteroid Trial. JAMA. 2006;295:1556-1565.
29. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelliere R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The periscope randomized controlled trial. JAMA. 2008;299:1561-1573. (Pubitemid 351482795)
30. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The Stradivarius Randomized Controlled Trial. JAMA. 2008;299:1547-1560. (Pubitemid 351482794)
31. Dresske B, Haendschke F, Lenz P, Ungefroren H, Jenisch S, Exner B, El Mokhtari NE, Lu T, Zavazava N, Faendrich F. WOFIE stimulates regulatory t cells: A 2-year follow-up of renal transplant recipients. Transplantation. 2006;81:1549-1557. (Pubitemid 43890892)